MedDataX Logo

Low Dose Atropine for Symptomatic Vitreous Floaters

NCT ID: NCT06174935

Last Updated: 2023-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-01

Study Completion Date

2024-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitreous Floaters

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atropine 0.01%

Patients will apply 1 drop daily of atropine 0.01%

Group Type EXPERIMENTAL

0.01% atropine ophthalmic drop

Intervention Type DRUG

0.01% atropine ophthalmic drop will be applied daily to the affected eye

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0.01% atropine ophthalmic drop

0.01% atropine ophthalmic drop will be applied daily to the affected eye

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Patients with vitreous hemorrhage, other significant media opacity or vitreoretinal pathology, or history of pars plana vitrectomy will be excluded.
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jeanette Du

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jeanette Du

Physician

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Retina Group of Washington

Reston, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jeanette Du, MD

Role: CONTACT

Phone: 844-749-3627

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jeanette Du, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1362664

Identifier Type: -

Identifier Source: org_study_id